UGIP20027, Dunne, CA209-7WU, Pancreatic Ductal Adenocarcinoma, SX-682, Nivolumab
Research Question:
To determine the maximum tolerable dose (MTD) of SX-682 in combination with nivolumab
in patients with metastatic pancreatic ductal adenocarcinoma who have completed at
least 16 weeks of first line chemotherapy treatment without evidence of disease progression.
Basic Study Information
Purpose:
The main purpose of this research study is to determine the maximum tolerable dose
(MTD) of SX-682 in combination with nivolumab in patients with metastatic pancreatic
ductal adenocarcinoma who have completed at least 16 weeks of first line chemotherapy
treatment without evidence of disease progression.
Location: University of Rochester Medical Center
Study Reference #: UGIP20027
Lead Researcher (Principal Investigator)
Lead Researcher:
Richard Dunne
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search